PIVYA® (pivmecillinam) tablets is a penicillin class antibiotic for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible bacteria.

This website is intended for US healthcare professionals only.

Efficacy & Safety Hero

Efficacy/Safety

Clinical Cure and Microbiological Response with PIVYA

Clinical Cure and Microbiological Response with PIVYA

PIVYA was evaluated against placebo (Trial 1), cephalexin (Trial 2), and ibuprofen (Trial 4) in three controlled clinical trials in women with uUTI with a positive baseline urine culture of >105 CFU/mL.1,a

Study Designs for PIVYA Pivotal Trials1

Trial Study Design PIVYA Regimen Comparator
Trial 1 Multicenter, randomized, double-blind, placebo-controlled; Sweden 185 mg 3 times daily for 7 days Placebo
Trial 2 Multicenter, randomized, double-blind, active-controlled; US 185 mg 3 times daily for 3 days Cephalexin 250 mg 4 times daily for 7 days
Trial 3 Open-label 185 mg 3 times daily for 3 days No comparator
Trial 4 Multicenter, randomized, double-blind, noninferiority; Denmark, Norway, Sweden 185 mg 3 times daily for 3 days Ibuprofen 600 mg 3 times daily for 3 days

a Efficacy was assessed in the micro-ITT population. Clinical cure and microbiological response definitions and test-of-cure timing varied by trial.

Clinical Cure Rates at Test of Cure1

PIVYA Comparator Treatment Difference
64% (87/137) Placebo: 23% (31/134) 40% (95% CI: 29, 52)
83% (105/127) Cephalexin: 85% (112/132) -2% (95% CI: -12, 8)
77% (81/105) Ibuprofen: 38% (45/119) 39% (95% CI: 27, 52)

Microbiological Response Rates at Test of Cure1

PIVYA Comparator Treatment Difference
87% (119/137) Placebo: 26% (35/134) 61% (95% CI: 51, 71)
76% (97/127) Cephalexin: 80% (106/132) -4% (95% CI: -15, 7)
74% (78/105) Ibuprofen: 54% (64/119) 21% (95% CI: 7, 34)

CFU/mL: Colony-forming units per milliliter.

Resistance and Recurrence

Recurrent uUTIb is also associated with greater antibiotic resistance. In a US retrospective study, urinary E. coli isolates from female patients with recurrent uUTI had higher rates of resistance to TMP-SMX and fluoroquinolones, as well as a higher prevalence of ESBL production, than isolates from patients with non-recurrent uUTI.2

Greater Resistance in Recurrent uUTI2

Urinary E. coli finding3 Recurrent uUTI Non-recurrent uUTI
TMP-SMX resistance 21.8% 18.7%
Fluoroquinolone resistance 14.2% 8.6%
ESBL-producing isolates 5.9% 4.1%

b In the 2025 American Urological Association/Canadian Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction, recurrent uUTI is defined by the AUA as ≥2 episodes within a 6-month period sometime within the preceding year.3

Established Safety and Tolerability

Pivmecillinam has more than 40 years of clinical experience, primarily in Europe and Canada. A systematic review of 110 publications supported pivmecillinam’s established safety and tolerability profile. Gastrointestinal adverse events were among the most commonly reported, while discontinuations due to adverse events were generally uncommon.4

In the clinical trials supporting the US approval of PIVYA, safety was evaluated in 579 adult women with uUTI. No serious adverse reactions were reported. The most common adverse reactions occurring in at least 2% of patients were nausea and diarrhea. In Trial 2 and Trial 3, the most common adverse reaction occurring in ≥1% of patients receiving PIVYA was nausea with an incidence of 1.4% in Trial 2 and 3.6% in Trial 3.1

Adverse Reactions Occurring in ≥1% of Patients Receiving PIVYA in Trial 11

Adverse Reactions (AR) PIVYA N=282 n (%) Placebo N=288 n (%)
Nausea 12 (4.3) 6 (2.1)
Diarrhea 6 (2.1) 2 (0.7)
Vulvovaginal candidiasis 5 (1.8) 0
Genital pruritus 5 (1.8) 4 (1.4)
Headache 4 (1.4) 1 (0.3)

An Additional uUTI Treatment Option During Pregnancy

PIVYA provides an additional oral option for appropriate pregnant patients—with no pregnancy dose adjustment required.1

Two observational cohort studies involving 42,223 women exposed to pivmecillinam during the first trimester found no increased risk of major birth defects compared with 50,099 women exposed to other antibacterial drugs.1,c

c Studies evaluating miscarriage and other adverse maternal or fetal outcomes are limited and have methodological limitations.1

Lactation: In a study of lactating cows given 8 mg/kg mecillinam IV, the concentration in milk was 0.1 and 0.7 μg/mL at 2 and 6 hours, respectively, and the total excretion in milk over the first 6 hours was 0.03% of the injected dose. The concentration of mecillinam in animal milk does not necessarily predict the concentration of drug in human milk.1

Prescribing consideration: Treatment before delivery may cause a false-positive newborn screening result for isovaleric acidemia. Prompt follow-up of a positive result is recommended.1

Why PIVYA?

About PIVYA Icon

About PIVYA

Learn about PIVYA, a first-line treatment for uncomplicated urinary tract infections with over 40 years of clinical experience.

Learn More
Resistance Icon

Resistance

Find out why antibiotic treatments are not always appropriate empiric choices.

Learn More
Prescription Icon

Prescribing PIVYA

What to know about starting your patients on PIVYA.

Prescribing Guide

Help Your Patients Save on Their Prescription for PIVYA

Most eligible commercially insured patients pay between $0 and $15 using the PIVYA copay savings card.

PIVYA Copay Card

Request samples for your office

Click the button below to fill out an online form to receive a free sample of PIVYA.

In compliance with the Prescription Drug Marketing Act regulations, incomplete request forms cannot be processed and samples will not be delivered.

References:
  1. PIVYA (pivmecillinam) Prescribing Information. Alembic Therapeutics; 2025.
  2. Fromer DL, et al. Urology. 2024;190:1-10.
  3. Ackerman AL, et al. J Urol. 2026;215:3-12.
  4. Kaye KS, et al. Clin Infect Dis. 2025;80:280-299.